Why did Colgate cut its organic sales growth guidance?

Full-year 2025 organic sales growth is now expected at 1%-2%, versus the low end of 2%-4% previously. Management cited slowing category growth in many markets, and about 70 basis points of the expected growth comes from the exit of low-margin private label pet sales. Year-to-date organic growth was 1.2%, so the new range is roughly in line with the current trend.

How large and how long is the restructuring program, and what will it cost?

The Strategic Growth and Productivity Program is a three-year initiative with estimated cumulative pre-tax charges of $200-$300 million once fully approved and implemented. About 65%-75% relates to employee costs such as severance, and 25%-35% to asset-related costs. Roughly 75%-85% will be cash, and substantially all charges are expected by December 31, 2028. The charges are spread across regions, with the largest shares in North America and Latin America.

Is Colgate's margin pressure getting worse?

Yes, in the near term. Q3 GAAP gross margin fell 170 basis points to 59.4%, and the Base Business decline was 190 basis points. Management now expects full-year gross margin of roughly 60.1%, in line with year-to-date results, versus roughly flat previously. Operating margin fell 60 basis points on a GAAP basis to 20.6%, and the program's savings are intended to help offset these pressures over time.

Does the filing show Colgate's cash generation and balance sheet are under strain?

Not materially. Nine-month operating cash flow was $2,745 million and free cash flow before dividends was $2,358 million, against dividends paid of $1,300 million. Total debt rose to $8,419 million from $7,949 million at year-end 2024, and net debt was $6,947 million. Working capital was negative 4.0% of sales. Cash flow covers the dividend, but the rise in debt and the restructuring cash costs bear watching.

CL 8-K: Earnings & Results & Financial Events

01—Abstract

Summary

Summary of the 8-K filed October 31, 2025. Cited figures are marked; the original filing is the authoritative source.

Colgate-Palmolive reported Q3 2025 results that were mixed: net sales rose 2.0% to $5,131 million^a, but organic sales grew only 0.4%, and the gain was held back by a 0.8-point drag from exiting low-margin private label pet sales.

GAAP EPS rose 1% to $0.91^b, and Base Business EPS was flat at $0.91. Gross margin fell 170 basis points to 59.4% on a GAAP basis (190 basis points on a Base Business basis), and operating profit declined 1% as reported and 2% on a Base Business basis. North America (organic sales -0.5%, operating profit down 8%) and Latin America (operating profit down 8%) were the weak spots, while Europe (operating profit up 16%) and Africa/Eurasia were the bright spots.

Management cut its full-year 2025 organic sales growth guidance to 1%-2%, from the low end of 2%-4%, and now includes roughly a 70 basis point drag from the private label pet exit. It maintained its EPS guidance of low-single-digit growth and now expects gross margin roughly in line with the year-to-date 60.1%, down from roughly flat previously. The filing also discloses the Strategic Growth and Productivity Program, a three-year restructuring with estimated cumulative pre-tax charges of $200^c-$300 million, about 75%-85% of which will be cash expenditures, to be substantially incurred by December 31, 2028.

For investors, the central questions are whether the 2030 strategy and the productivity program can restore organic growth and margins, and whether the savings from the program will offset the pressure from slowing category growth, tariffs, and gross margin erosion. Balance sheet metrics are stable, with year-to-date operating cash flow of $2,745 million^d and free cash flow before dividends of $2,358 million, though total debt rose to $8,419 million. Note that the filing is partly a furnished press release, and the forward-looking statements it contains carry the usual risks.

02—Key points

Key Highlights

Organic sales grew just 0.4% in Q3 2025 (net sales +2.0%), with a 0.8-point drag from exiting private label pet sales.
GAAP EPS rose 1% to $0.91; Base Business EPS was flat at $0.91, and Base Business operating profit fell 2%.
Gross margin fell 170 bps to 59.4% (GAAP) and 190 bps on a Base Business basis, reflecting cost and pricing pressure.
Full-year 2025 organic sales growth guidance was cut to 1%-2%, from the low end of 2%-4%; EPS guidance was maintained at low-single-digit growth.
Strategic Growth and Productivity Program: $200-$300 million in cumulative pre-tax charges through 2028, with 75%-85% expected to be cash, mainly employee-related severance.
Regional divergence: Europe operating profit rose 16% and Africa/Eurasia rose 5%, while North America (-8%) and Latin America (-8%) declined.
Market share strength continued, with global toothpaste share at 41.2% and manual toothbrush share at 32.4% year to date.

03—Questions

Frequently Asked Questions

Why did Colgate cut its organic sales growth guidance?
Full-year 2025 organic sales growth is now expected at 1%-2%, versus the low end of 2%-4% previously. Management cited slowing category growth in many markets, and about 70 basis points of the expected growth comes from the exit of low-margin private label pet sales. Year-to-date organic growth was 1.2%, so the new range is roughly in line with the current trend.
How large and how long is the restructuring program, and what will it cost?
The Strategic Growth and Productivity Program is a three-year initiative with estimated cumulative pre-tax charges of $200-$300 million once fully approved and implemented. About 65%-75% relates to employee costs such as severance, and 25%-35% to asset-related costs. Roughly 75%-85% will be cash, and substantially all charges are expected by December 31, 2028. The charges are spread across regions, with the largest shares in North America and Latin America.
Is Colgate's margin pressure getting worse?
Yes, in the near term. Q3 GAAP gross margin fell 170 basis points to 59.4%, and the Base Business decline was 190 basis points. Management now expects full-year gross margin of roughly 60.1%, in line with year-to-date results, versus roughly flat previously. Operating margin fell 60 basis points on a GAAP basis to 20.6%, and the program's savings are intended to help offset these pressures over time.
Does the filing show Colgate's cash generation and balance sheet are under strain?
Not materially. Nine-month operating cash flow was $2,745 million and free cash flow before dividends was $2,358 million, against dividends paid of $1,300 million. Total debt rose to $8,419 million from $7,949 million at year-end 2024, and net debt was $6,947 million. Working capital was negative 4.0% of sales. Cash flow covers the dividend, but the rise in debt and the restructuring cash costs bear watching.

04—Continue

← View all 8-K filings